Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Market Report 2026" has been added to ResearchAndMarkets.com's offering.
The glioblastoma multiforme market has demonstrated significant growth and is poised for further expansion. In 2025, the market was valued at $2.7 billion, projected to reach $2.92 billion in 2026, with a CAGR of 8.1%. This historical growth is attributed to limited treatment options, advancements in neuro-oncology, chemotherapy standardization, and enhanced imaging technologies.
Future projections indicate a climb to $3.94 billion by 2030, sporting a CAGR of 7.8%. This growth is driven by the development of novel targeted drugs, expansion of immunotherapy research, personalized cancer treatments adoption, and increased funding for brain cancer research.
Rising brain disorder incidences are propelling market expansion. Factors such as aging populations and enhanced diagnostics contribute to an increased understanding of brain disorders, facilitating advancements in GBM research for earlier detection and innovative treatments. In 2025, Dementia Australia reported that approximately 433,300 Australians live with dementia, with projections skyrocketing to 812,500 by 2054. Younger-onset dementia is expected to affect 41,000 people by the same year.
Leading companies are focusing on advanced therapies, like CAR T-cell therapies. Chimeric Therapeutics Limited initiated a Phase IB clinical trial for CHM 1101 (CLXT CAR T) therapy in June 2023, targeting recurrent or progressive GBM, aiming to establish safety and efficacy. Similarly, Merck & Co. strengthened its oncology pipeline by acquiring Modifi Biosciences in October 2024, focusing on small-molecule platforms targeting cancer cells with DNA repair defects.
Key players in this market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, and several others. North America dominated the market in 2025, while Asia-Pacific is projected to be the fastest-growing region. The influence of tariffs is noteworthy, increasing costs of imported oncology drugs and prompting domestic innovation.
Reasons to Purchase:
- Gain a global perspective with comprehensive coverage across 16 geographies.
- Analyze the impact of macro factors like geopolitical tensions, trade policies, economic fluctuations, and regulatory changes.
- Develop tailored regional and national strategies using local data insights.
- Identify investment opportunities in growth segments.
- Use forecast data and market drivers to outperform competitors.
- Deepen understanding of customer bases through end-user analysis.
- Benchmark against competitors on market share, innovation, and brand strength.
- Evaluate market potential through total addressable market and attractiveness scoring.
- Support presentations with high-quality, reliable data and analysis.
- Receive updates with the latest data and an Excel data sheet for analysis.
Markets Covered: Drug Class: Chemotherapy Agents; Temozolomide; Carmustine; Lomustine; Other Drug Classes. Diagnostic Tools: MRI, CT Scan, Biopsy. Treatment Type: Surgery, Radiation, Chemotherapy, Immunotherapy, Tumor-Treating Field Therapy. End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers.
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Regions: Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Data and Delivery Format: Ratios of market size to related markets, GDP proportions, expenditure per capita. Historic and forecast data segmented by country and region. Available in Word, PDF, or Interactive Format + Excel Dashboard.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $2.92 Billion |
| Forecasted Market Value (USD) by 2030 | $3.94 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
The companies featured in this Glioblastoma Multiforme market report include:
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Novartis International AG
- Eli Lilly and Company
- Amgen Inc.
- Merck KGaA
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Zydus Pharmaceuticals (USA) Inc.
- Accord Healthcare Inc.
- Sumitomo Dainippon Pharma Oncology Inc.
- Karyopharm Therapeutics Inc.
- ITM Isotope Technologies Munich SE
- Azurity Pharmaceuticals Inc.
- Genenta Science S.p.A.
- Chimeric Therapeutics Limited
- VBI Vaccines Inc.
For more information about this report visit https://www.researchandmarkets.com/r/6bzyw4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
